Zastosowanie preparatu łączonego amlodypiny i atorwastatyny w terapii nadciśnienia tętniczego, dyslipidemii i choroby niedokrwiennej serca Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2014
Słowa kluczowe:
nadciśnienie tętnicze, dyslipidemia, choroba niedokrwienna serca, amlodypina, atorwastatyna
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nadciśnienie tętnicze i dyslipidemia to jedne z najczęściej stwierdzanych czynników ryzyka sercowo-naczyniowego, przede wszystkim choroby niedokrwiennej serca oraz chorób naczyniowo-mózgowych. Pacjenci stosujący leki hipotensyjne często wymagają równoczesnego stosowania leków hipolipemizujących. Wśród leków hipotensyjnych bardzo często, zarówno w monoterapii, jak i w terapii skojarzonej, stosuje się antagonistów wapnia. W terapii dyslipidemii podstawą leczenia farmakologicznego są statyny. Preparat łączony zawierający amlodypinę i atorwastatynę stanowi nową opcję terapeutyczną dla pacjentów z nadciśnieniem i współistniejącą dyslipidemią lub chorobą niedokrwienną serca. Autorzy artykułu przedstawiają najnowsze dane dotyczące bezpieczeństwa i efektów stosowania takiego skojarzenia leków.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Wełnicki , M., Adamska-Wełnicka , A., & Mamcarz , A. (2014). Zastosowanie preparatu łączonego amlodypiny i atorwastatyny w terapii nadciśnienia tętniczego, dyslipidemii i choroby niedokrwiennej serca . Medycyna Faktów , 7(1(22), 14-19. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2376
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. 2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 2013 [online: doi:10.1093/eurheartj/eht151].
2. Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11.000 participants from 42 trials. Am. J. Med. 2009; 122: 290-300.
3. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013 [online: doi:10.1093/eurheartj/eht296].
4. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Developed with the special contribution of: European Association for Cardiovascular Prevention & Rehabilitation. Eur. Heart J. 2011; 32: 1769-1818.
5. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2012; 33: 1635-1701.
6. Wiszniewska M., Kobayashi A., Członkowska A.: Postępowanie w udarze mózgu. Skrót Wytycznych Grupy Ekspertów Sekcji Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego z 2012 roku. Polski Przegląd Neurologiczny 2012; 4(8).
7. Bakris G.L., Sarafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized, controlled trial. Lancet 2010 [online: doi: 10.1016/S0140-6736(09)62100-0].
8. Sever P.S., Dahlöf B., Poulter N.R. et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet 2003; 361: 1149-1158.
9. Julius S., Kjeldsen S.E., Weber M. et al.; VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
10. Cannon C.P., Braunwald E., McCabe C.H. et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350(15): 1495-1504.
11. LaRosa J.C., Grundy S.M., Waters D.D. et al.; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005; 352: 1425-1435.
12. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association-European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany.
13. Dorresteijn J.A., Boekholdt S.M., van der Graaf Y. et al.: High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation 2013; 127(25): 2485-93.
14. Cowie M.R.: Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/ atorvastatin single-pill therapy. J. Clin. Pract. 2005; 59(7): 839-46.
15. McKeage K., Siddiqui M.A.: Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am. J. Cardiovasc. Drugs 2008; 8(1): 51-67.
16. Richard Hobbs F.D., Gensini G., John Mancini G.B. et al.: International open-label studies to assess the efficacy and safety of single-pill amlodipine/ atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur. J. Cardiovasc. Prev. Rehabil. 2009; 16(4): 472-80.
17. Curran M.P.: Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the preventionof cardiovascular disease. Drugs 2010; 70(2): 191-213.
18. Delgado-Montero A., Zamorano J.L.: Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opin. Pharmacother. 2012; 13(18): 2673-85.
19. Bashir S., Sherwani M.U., Shabbir I. et al.: Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia. J. Ayub. Med. Coll. Abbottabad 2011; 23(3): 97-100.
20. Simons L.A., Ortiz M., Calcino G.: Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med. J. Aust. 2011; 195(3): 134-7.
21. Li M., Xu A., Lam K.S. et al.: Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin. Postgrad. Med. 2011; 123(6): 66-71.
22. Koh K.K., Quon M.J., Han S.H. et al.: Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int. J. Cardiol. 2011; 146(3): 319-25.
2. Wald D.S., Law M., Morris J.K. et al. Combination therapy versus monotherapy in reducing blood pressure: metaanalysis on 11.000 participants from 42 trials. Am. J. Med. 2009; 122: 290-300.
3. 2013 ESC guidelines on the management of stable coronary artery disease. The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur. Heart J. 2013 [online: doi:10.1093/eurheartj/eht296].
4. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Developed with the special contribution of: European Association for Cardiovascular Prevention & Rehabilitation. Eur. Heart J. 2011; 32: 1769-1818.
5. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur. Heart J. 2012; 33: 1635-1701.
6. Wiszniewska M., Kobayashi A., Członkowska A.: Postępowanie w udarze mózgu. Skrót Wytycznych Grupy Ekspertów Sekcji Chorób Naczyniowych Polskiego Towarzystwa Neurologicznego z 2012 roku. Polski Przegląd Neurologiczny 2012; 4(8).
7. Bakris G.L., Sarafidis P.A., Weir M.R. et al.: Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized, controlled trial. Lancet 2010 [online: doi: 10.1016/S0140-6736(09)62100-0].
8. Sever P.S., Dahlöf B., Poulter N.R. et al.: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet 2003; 361: 1149-1158.
9. Julius S., Kjeldsen S.E., Weber M. et al.; VALUE trial group: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
10. Cannon C.P., Braunwald E., McCabe C.H. et al.; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med. 2004; 350(15): 1495-1504.
11. LaRosa J.C., Grundy S.M., Waters D.D. et al.; Treating to New Targets (TNT) Investigators: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 2005; 352: 1425-1435.
12. de Zeeuw D.: Different renal protective effects of atorvastatin and rosuvastatin in diabetic and non-diabetic renal patients with proteinuria. Results of the PLANET trials. 2010 European Renal Association-European Dialysis and Transplant Association Congress; June 27, 2010; Munich, Germany.
13. Dorresteijn J.A., Boekholdt S.M., van der Graaf Y. et al.: High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation 2013; 127(25): 2485-93.
14. Cowie M.R.: Simultaneous treatment of hypertension and dyslipidaemia may help to reduce overall cardiovascular risk: focus on amlodipine/ atorvastatin single-pill therapy. J. Clin. Pract. 2005; 59(7): 839-46.
15. McKeage K., Siddiqui M.A.: Amlodipine/atorvastatin fixed-dose combination: a review of its use in the prevention of cardiovascular disease and in the treatment of hypertension and dyslipidemia. Am. J. Cardiovasc. Drugs 2008; 8(1): 51-67.
16. Richard Hobbs F.D., Gensini G., John Mancini G.B. et al.: International open-label studies to assess the efficacy and safety of single-pill amlodipine/ atorvastatin in attaining blood pressure and lipid targets recommended by country-specific guidelines: the JEWEL programme. Eur. J. Cardiovasc. Prev. Rehabil. 2009; 16(4): 472-80.
17. Curran M.P.: Amlodipine/Atorvastatin: a review of its use in the treatment of hypertension and dyslipidaemia and the preventionof cardiovascular disease. Drugs 2010; 70(2): 191-213.
18. Delgado-Montero A., Zamorano J.L.: Atorvastatin calcium plus amlodipine for the treatment of hypertension. Expert Opin. Pharmacother. 2012; 13(18): 2673-85.
19. Bashir S., Sherwani M.U., Shabbir I. et al.: Efficacy of fix dose combination (atorvastatin and amlodipine) in treatment of uncontrolled hypertension and dyslipidemia. J. Ayub. Med. Coll. Abbottabad 2011; 23(3): 97-100.
20. Simons L.A., Ortiz M., Calcino G.: Persistence with a single pill versus two pills of amlodipine and atorvastatin: the Australian experience, 2006-2010. Med. J. Aust. 2011; 195(3): 134-7.
21. Li M., Xu A., Lam K.S. et al.: Impact of combination therapy with amlodipine and atorvastatin on plasma adiponectin levels in hypertensive patients with coronary artery disease: combination therapy and adiponectin. Postgrad. Med. 2011; 123(6): 66-71.
22. Koh K.K., Quon M.J., Han S.H. et al.: Additive beneficial effects of atorvastatin combined with amlodipine in patients with mild-to-moderate hypertension. Int. J. Cardiol. 2011; 146(3): 319-25.